Zydus Lifesciences completes acquisition of Assertio Holdings at $23.50 per share

What Zydus Lifesciences announced

Zydus Lifesciences Ltd. disclosed that it has successfully completed a cash tender offer for all outstanding shares of Assertio Holdings, Inc. (Nasdaq: ASRT). The offer, executed through Zydus’s wholly‑owned subsidiary Zara Merger Sub Inc., was concluded on 16 June 2026, resulting in Assertio becoming a wholly‑owned subsidiary of Zydus.

Details of the cash tender offer

The tender offer was priced at $23.50 per share of Assertio common stock, payable without interest and subject to applicable withholding taxes. The offer remained open until one minute after 11:59 p.m. Eastern Time on 15 June 2026. At that deadline, 4,286,488 shares were validly tendered and not withdrawn, representing approximately 66.32 % of Assertio’s total issued and outstanding shares. All tendered shares were accepted for payment, and Zydus indicated that it would promptly remit the cash consideration to shareholders.

Merger mechanics and post‑completion structure

Following the tender offer, Zydus intends to consummate a merger in which Zara Merger Sub Inc. will merge into Assertio Holdings. Assertio will survive as the surviving corporation, but it will no longer be listed on the Nasdaq Global Market. After the merger, Assertio will be a wholly‑owned subsidiary of Zydus Lifesciences. Shares of Assertio that were not tendered will be cancelled and their holders will receive cash equal to the $23.50 offer price per share, less any required tax deductions.

Key facts at a glance

Why this matters for investors

The acquisition gives Zydus Lifesciences a direct foothold in the U.S. biopharma market through Assertio’s portfolio of specialty pharmaceuticals. By acquiring a controlling 66 % stake, Zydus gains the ability to integrate Assertio’s products and pipelines with its own global operations. The transaction is cash‑based; however, the filing does not disclose the exact financing mix, leaving investors without details on whether existing cash reserves, debt facilities, or a combination thereof were used. The cancellation of non‑tendered shares and cash settlement at the same $23.50 price ensures that all remaining shareholders receive the same consideration, eliminating any differential treatment.

From a corporate‑governance perspective, the merger was executed through a wholly‑owned subsidiary, a common structure that isolates liabilities and simplifies the integration process. The delisting of Assertio from Nasdaq removes a public reporting requirement for the subsidiary, consolidating financial reporting under Zydus’s existing framework.

Conclusion

Zydus Lifesciences has completed its cash tender offer for Assertio Holdings, acquiring roughly two‑thirds of the target’s shares at $23.50 each and finalising the merger on 16 June 2026. Assertio will now operate as a wholly‑owned subsidiary, with any remaining shares cancelled and cash‑settled. While the acquisition expands Zydus’s international presence, the filing does not provide specifics on the financing arrangement, leaving that aspect undisclosed for now.